Page 1 of 65312345...102030...Last »




Low back and neck pain; 6 months after stem cell therapy by Dr Harry Adelson Low back and neck pain; 6 months after stem cell therapy by Dr Harry Adelson www.docereclinics.com. By: Harry Adelson, N.D.

Source Link(s) Are Here

Low back and neck pain; 6 months after stem cell therapy by Dr Harry Adelson - Video

Theres controversy surrounding the use of stem cells, particularly in humans. But stem cell therapy is being used to treat beloved pets. Here’s how it works in animals.



Source Link(s) Are Here

Stem Cell Therapy for Pets - WebMD

TOKYO–(BUSINESSWIRE)– Shiseido Co., Ltd. (TOKYO:4911) announces plans to open the Shiseido Cell-Processing and Expansion Center (SPEC) on May 1, 2014. The center, located in the in the Kobe Biomedical Innovation Cluster in Kobe, Japan, will centralize research and development on hair regenerative medicine with an aim toward commercialization



Source Link(s) Are Here

Shiseido Opens Research Facility Dedicated to Hair Regeneration

The Orbsen Therapeutics team. The company has already worked on a number of FP7-funded cell therapy projects Orbsen Therapeutics, a spin-out from NUI Galways Regenerative Medicine Institute (Remedi) has announced plans to partner with the University of Birmingham in a 6 million project to fight liver disease



Source Link(s) Are Here

Orbsen Therapeutics to take part in 6m liver disease clinical trial




Einstein On: Stem Cells, Dr. Paul Frenette (2 of 2): Benefits and Risks of Therapy Einstein On: Stem Cells, Dr. Paul Frenette (2 of 2): Benefits and Risks of Therapy Tony Velasquez and Karmina Constantino talk to Philippine Stem Cell Societ..

Source Link(s) Are Here

Einstein On: Stem Cells, Dr. Paul Frenette (2 of 2): Benefits and Risks of Therapy - Video

Tuesday, April 22 11:57:06 Orbsen Therapeutics, a spin-out from NUI Galway’s Regenerative Medicine Institute (REMEDI), is to partner with the University of Birmingham in a E6 million EU FP7 funded MERLIN project to fight liver disease. The EU FP7-funded project known by the acronym “MERLIN” (MEsynchymal stem cells to Reduce Liver INflammation) is led by Professor Phil Newsome, Clinical Director of the Birmingham University Stem Cell Centre



Source Link(s) Are Here

Irish cell therapy firm in E6m research

The Orbsen Therapeutics team.



Source Link(s) Are Here

Orbsen Therapeutics to take part in 6million liver disease clinical trial

Shiseido Co., Ltd. (TOKYO:4911) announces plans to open the Shiseido Cell-Processing and Expansion Center (SPEC) on May 1, 2014. The center, located in the in the Kobe Biomedical Innovation Cluster in Kobe, Japan, will centralize research and development on hair regenerative medicine with an aim toward commercialization



Source Link(s) Are Here

Shiseido Cell-Processing and Expansion Center to be opened in Kobe, Japan

Lawrence LeBlond for redOrbit.com Your Universe Online Invasive bladder cancer (IBC), a malignant disease that currently affects more than 375,000 people worldwide, has been found to be caused by a single type of cell in the lining of the bladder, according to researchers with the Stanford University School of Medicine. The researchers say this is the first study to pinpoint the normal cell type that can give rise to IBC. It is also the first study to show that most bladder cancers and their precancerous lesions arise from just one cell, which could also explain why many bladder cancers recur after therapy



Source Link(s) Are Here

Single Cell Type Found To Cause Most Invasive Bladder Cancers: Study

A single type of cell in the lining of the bladder is responsible for most cases of invasive bladder cancer, according to researchers at the Stanford University School of Medicine. Their study, conducted in mice, is the first to pinpoint the normal cell type that can give rise to invasive bladder cancers



Source Link(s) Are Here

Stanford researchers identify normal cell type that gives rise to most invasive bladder cancers